Chetasi Talati, MD, discusses the design of a chart review study with venetoclax and hypomethylating agents in older patients with newly-diagnosed acute myeloid leukemia.
Chetasi Talati, MD
Advertisement
Articles by Chetasi Talati, MD
Chetasi Talati, MD, discusses the rationale for investigating venetoclax in acute myeloid leukemia.
Chetasi Talati, MD, discusses the ongoing safety analysis of venetoclax (Venclexta)-based combinations in patients with newly diagnosed acute myeloid leukemia.
Advertisement
Latest Updated Articles
Dr. Talati on Rationale for Collecting Real-World Data on Venetoclax/HMA Combos in AMLPublished: July 8th 2020 | Updated:
Dr. Talati on Real-World Data With Venetoclax Combinations in AMLPublished: June 13th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5